Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1

Interventions

Carboplatin 129pembrolizumab 124Cisplatin 114Paclitaxel 102Gemcitabine 85Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 59Cyclophosphamide 59Pemetrexed 55Bevacizumab 54durvalumab 53Doxorubicin 52Radiotherapy 49Capecitabine 49Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 40Etoposide 38Letrozole 36atezolizumab 35Nivolumab 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Procarbazine × 90 days × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡